Dow Jones
38.869,85 +17,58 (+0,05%) Nasdaq
16.338,94 -10,30 (-0,06%) Nikkei 225
38.835,10 +599,03 (+1,57%) EUR/USD
1,0757 -0,0016 (-0,15%) Bitcoin EUR
58.870,32 +126,61 (+0,22%) CMC Crypto 200
1.314,24 -50,88 (-3,73%)
Vaxcyte, Inc. (PCVX)
| Chiusura precedente | 66,40 |
| Aperto | 66,40 |
| Denaro | 66,78 x 100 |
| Lettera | 66,89 x 100 |
| Min-Max giorno | 65,86 - 67,53 |
| Intervallo di 52 settimane | 44,20 - 82,04 |
| Volume | |
| Media Volume | 721.688 |
| Capitalizzazione | 7,263B |
| Beta (5 anni mensile) | 0,89 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -4,14 |
| Prossima data utili | 07 mag 2024 - 10 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 103,29 |
GlobeNewswireVaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)
-- New Agreement to Establish Global Commercial Manufacturing Capacity for Vaxcyte's PCV Candidates, VAX-24 and VAX-31, in Adult and Pediatric Populations -- -- Expanded Collaboration Builds on Vaxcyte’s Current Strategy to Conduct Initial Commercial Launch of VAX-24 in Adults from Existing Lonza Facilities in Visp (CH) -- -- Long-Standing Relationship Between the Companies Further Enhanced as Vaxcyte Progresses Lead Vaccine Candidate into Late-Stage Clinical Development -- -- New Purpose-Built
- GlobeNewswire
Vaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
SAN CARLOS, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the 2023 Cantor Fitzgerald Global Healthcare Conference in New York on Tuesday, September 26, 2023 at 11:40 a.m. ET / 8:40 a.m. PT. A live webcast of the fireside chat can be accessed through
- GlobeNewswire
Vaxcyte Reports Second Quarter 2023 Financial Results and Provides Business Update
-- Advanced Ongoing VAX-24 Phase 2 Infant Study to Second Stage, Dosing First New Participants in July 2023; Topline Data from Primary Immunization Series Expected by 2025 -- -- Completed Phase 2 VAX-24 Adult Program for the Prevention of Invasive Pneumococcal Disease (IPD); Topline Phase 3 Data Expected in 2025 -- -- VAX-31 Adult Investigational New Drug (IND) Application Clearance Expected in Fourth Quarter of 2023; Topline Phase 1/2 Data Expected in 2024 -- -- $1.4 Billion in Cash, Cash Equiv
